246 related articles for article (PubMed ID: 25104879)
1. CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development?
Dos Santos Virgilio F; Pontes C; Dominguez MR; Ersching J; Rodrigues MM; Vasconcelos JR
Mediators Inflamm; 2014; 2014():243786. PubMed ID: 25104879
[TBL] [Abstract][Full Text] [Related]
2. Costimulatory Effects of an Immunodominant Parasite Antigen Paradoxically Prevent Induction of Optimal CD8 T Cell Protective Immunity.
Eickhoff CS; Zhang X; Vasconcelos JR; Motz RG; Sullivan NL; O'Shea K; Pozzi N; Gohara DW; Blase JR; Di Cera E; Hoft DF
PLoS Pathog; 2016 Sep; 12(9):e1005896. PubMed ID: 27642757
[TBL] [Abstract][Full Text] [Related]
3. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
[TBL] [Abstract][Full Text] [Related]
4. Understanding CD8
Acosta Rodríguez EV; Araujo Furlan CL; Fiocca Vernengo F; Montes CL; Gruppi A
Trends Parasitol; 2019 Nov; 35(11):899-917. PubMed ID: 31607632
[TBL] [Abstract][Full Text] [Related]
5. Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance.
Tzelepis F; de Alencar BC; Penido ML; Claser C; Machado AV; Bruna-Romero O; Gazzinelli RT; Rodrigues MM
J Immunol; 2008 Feb; 180(3):1737-48. PubMed ID: 18209071
[TBL] [Abstract][Full Text] [Related]
6. Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling.
Martin DL; Murali-Krishna K; Tarleton RL
Infect Immun; 2010 Jul; 78(7):3154-9. PubMed ID: 20457790
[TBL] [Abstract][Full Text] [Related]
7. Swimming against the current: genetic vaccination against Trypanosoma cruzi infection in mice.
Rodrigues MM; de Alencar BC; Claser C; Tzelepis F; Silveira EL; Haolla FA; Dominguez MR; Vasconcelos JR
Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():281-7. PubMed ID: 19753486
[TBL] [Abstract][Full Text] [Related]
8. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
Chowdhury IH; Lokugamage N; Garg NJ
Front Immunol; 2020; 11():595039. PubMed ID: 33414785
[TBL] [Abstract][Full Text] [Related]
9. Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine.
Vasconcelos JR; Bruña-Romero O; Araújo AF; Dominguez MR; Ersching J; de Alencar BC; Machado AV; Gazzinelli RT; Bortoluci KR; Amarante-Mendes GP; Lopes MF; Rodrigues MM
PLoS Pathog; 2012; 8(5):e1002699. PubMed ID: 22615561
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS
Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671
[TBL] [Abstract][Full Text] [Related]
11. CD8
Lasso P; Mateus J; González JM; Cuéllar A; Puerta C
Methods Mol Biol; 2019; 1955():349-361. PubMed ID: 30868540
[TBL] [Abstract][Full Text] [Related]
12. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.
Pereira IR; Vilar-Pereira G; Marques V; da Silva AA; Caetano B; Moreira OC; Machado AV; Bruna-Romero O; Rodrigues MM; Gazzinelli RT; Lannes-Vieira J
PLoS Pathog; 2015 Jan; 11(1):e1004594. PubMed ID: 25617628
[TBL] [Abstract][Full Text] [Related]
13. Limited Foxp3
Araujo Furlan CL; Tosello Boari J; Rodriguez C; Canale FP; Fiocca Vernengo F; Boccardo S; Beccaria CG; Adoue V; Joffre O; Gruppi A; Montes CL; Acosta Rodriguez EV
Front Immunol; 2018; 9():2555. PubMed ID: 30455700
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.
Rosenberg CS; Zhang W; Bustamante JM; Tarleton RL
Infect Immun; 2016 Sep; 84(9):2627-38. PubMed ID: 27354447
[TBL] [Abstract][Full Text] [Related]
15. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
16. Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses.
Wizel B; Nunes M; Tarleton RL
J Immunol; 1997 Dec; 159(12):6120-30. PubMed ID: 9550413
[TBL] [Abstract][Full Text] [Related]
17. Trypanosoma cruzi infection from the view of CD8+ T cell immunity--an infection model for developing T cell vaccine.
Miyahira Y
Parasitol Int; 2008 Mar; 57(1):38-48. PubMed ID: 17728174
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
Gupta S; Garg NJ
PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
[TBL] [Abstract][Full Text] [Related]
19. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
[TBL] [Abstract][Full Text] [Related]
20. The Combined Deficiency of Immunoproteasome Subunits Affects Both the Magnitude and Quality of Pathogen- and Genetic Vaccination-Induced CD8+ T Cell Responses to the Human Protozoan Parasite Trypanosoma cruzi.
Ersching J; Vasconcelos JR; Ferreira CP; Caetano BC; Machado AV; Bruna-Romero O; Baron MA; Ferreira LR; Cunha-Neto E; Rock KL; Gazzinelli RT; Rodrigues MM
PLoS Pathog; 2016 Apr; 12(4):e1005593. PubMed ID: 27128676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
